{
  "docId": "019de076-b0fc-7764-be49-9cb0f9de8ba9",
  "docSlug": "ed8052d583ef5c8745075e02dbad124b",
  "documentTitle": "MAIA Biotechnology | Investor Presentation Deck | 31 slides",
  "authorId": "maia-biotechnology",
  "authorName": "MAIA Biotechnology",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 31,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The chart demonstrates tumor volume reduction over time, highlighting the efficacy of the THIO + Atezo combination.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b0fc-7764-be49-9cb0f9de8ba9/10",
  "deckHref": "/decks/019de076-b0fc-7764-be49-9cb0f9de8ba9",
  "deckJsonHref": "/decks/019de076-b0fc-7764-be49-9cb0f9de8ba9.json",
  "deckAnchorHref": "/decks/019de076-b0fc-7764-be49-9cb0f9de8ba9#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.58,
        "x": 0.38,
        "y": 0.18
      },
      "kind": "chart",
      "text": "Tumor volume over time for Control, Atezo, THIO, and THIO+Atezo groups",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "43c35a07-60c3-4875-b56b-3caf8ee9dba0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.35,
        "x": 0.03,
        "y": 0.2
      },
      "kind": "list",
      "text": "THIO followed by CPI results in 60% complete response\nNo recurrence after long-term follow-up\nAnticancer immune memory has been induced: no cancer after rechallenge with 5x more lung cancer (LLC) cells with no additional therapy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ebc6279c-eccf-4f2b-ab34-dd9c91cd0c56",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.03,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "Mender et al, Cancer Cell, 2020; THIO followed by Tecentriq (atezolizumab; Roche/Genentech) tested first; repeated later with THIO followed by Keytruda (pembrolizumab; Merck); and Libtayo (cemiplimab; Regeneron)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e191e2ba-2c02-4930-92e6-25c4d691c6d1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "THIO-101 – RATIONALE",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "10a8fb0c-a8d0-4c47-8ad8-02d193a6c399",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}